马萨诸塞州剑桥 - 沙雷普塔治疗公司 ( Sarepta Therapeutics, Inc.) (NASDAQ:SRPT)周三宣布，新西兰药品管理局 (Medsafe)已批准其SRP-1005用于亨廷顿病治疗的临床试验申请。根据 InvestingPro 数据，该公司目前股价为$20.28，过去一周股价下跌近5%。

Investors in Sarepta Therapeutics Inc (Symbol: SRPT) saw new options begin trading today, for the October 31st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

As of December 6, 2025, the average one-year price target for Sarepta Therapeutics is $29.96/share. The forecasts range from a low of $5.05 to a high of $194.25. The average price target represents an ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth ...

Sarepta Therapeutics SRPT announced positive three-year top-line data from Part 1 of the phase III EMBARK study, evaluating ...

Bank of America downgraded Sarepta Therapeutics (NASDAQ:SRPT) to Underperform from Neutral on Wednesday, becoming the latest brokerage to issue a bearish view on the company, citing safety concerns ...

LOS ANGELES, Aug. 25, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations ...

Sarepta's turnaround is just beginning, with decisive management actions like layoffs boosting confidence and saving $100 million annually. The market had priced in the worst for Elevidys, but the FDA ...

If you are wondering whether Sarepta Therapeutics' current share price offers value or just fresh risk, you are not alone. After a very steep 82.1% share price decline over the last year and a 4.6% ...